Evidence-Based Medicine Guidelines
Natalizumab for induction of remission in Crohn's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Natalizumab for Induction of Remission in Crohn's Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/453921/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease.
Natalizumab for induction of remission in Crohn's disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/453921/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease. Accessed December 21, 2024.
Natalizumab for induction of remission in Crohn's disease. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/453921/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease
Natalizumab for Induction of Remission in Crohn's Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/453921/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Natalizumab for induction of remission in Crohn's disease
ID - 453921
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/453921/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
